Mini-review: androgen receptor phosphorylation in prostate cancer

Garrett Daniels¹, Zhiheng Pei¹,²,⁴,⁵, Susan K Logan²,³,⁴, Peng Lee¹,²,⁴,⁵

Departments of ¹Pathology, ²Urology, ³Pharmacology, ⁴NYU Cancer Institute, ⁵New York Harbor Healthcare System, New York University School of Medicine, New York, NY, USA

Received November 12, 2013; Accepted December 15, 2013; Epub December 25, 2013; Published December 30, 2013

Abstract: Androgen receptor (AR) plays an important role in the tumorigenesis and progression of prostate cancer (PCa), and is the primary therapeutic target for PCa treatment. AR activity can be regulated via phosphorylation at multiple phosphorylation sites within the protein. Modifications by phosphorylation alter AR function, including its cellular localization, stability and transcriptional activity, ultimately leading to changes in cancer cell biology and disease progression. Here we present a brief overview of AR phosphorylation sites in PCa, focusing on functional roles of phospho-AR (p-AR) species, relevance in PCa disease progression, and potential as biomarkers and/or therapeutic targets through the use of kinase inhibitors. Additionally, recent evidence has shown the important role of AR activity in the cancer associated stroma on PCa growth and progression. The phosphorylation status of epithelial and stromal AR may be distinct; however, the current data available on stromal AR phosphorylation is limited. Further research will determine global view on the synergistic effects of phosphorylation across multiple AR sites in both epithelial and stromal cells and validate whether together they can be used as prognostic markers and/or effective therapeutic targets for PCa.

Keywords: Androgen receptor, phosphorylation, prostate cancer
AR phosphorylation in prostate cancer

of Serine-81 also facilitates AR chromatin recruitment and transcriptional activity [12]. Functionally, phosphorylation at AR S81 promotes cell growth [13]. AR phosphorylation at S213 by Akt has been shown to either inhibit or promote cell growth in different cell contexts [14]. Phosphorylation of S213 by the PIM1S kinase isoform facilitates recruitment of E3 ubiquitin ligase Mdm2 and destabilizes AR protein [15]. Phosphorylation of S578 by PAK6 also leads to AR degradation [16].

Recurrent and in particular, castration resistant prostate cancer (CRPCa) is a clinically challenging condition that occurs when PCa becomes resistant to androgen ablation therapy. There is evidence that S515 phosphorylation may be a predictive marker for relapse in PCa [17]. Prognosis for patients with CRPCa is poor and multiple mechanisms have been proposed to explain the way PCa evades androgen ablation therapy. Even in the absence of androgens, AR is critical for the growth of CRPCa and still remains the primary therapeutic target [18-20]. Activation of AR by phosphorylation is one potential mechanism for the development of CRPCa. Even after androgen ablation therapy there is still evidence of low levels of androgens in the tumor microenvironment which aid in driving the formation of CRPCa [21]. Phosphorylation of AR at S81, S213 and S790 occurs in low androgen environments and may sensitize AR to low androgen conditions and be an indicator for CRPCa [11, 22]. Further, phosphorylation of AR at T850 by the PIM1 isoform PIM1-L leads to recruitment of the E3 ligase RNF6 and promotes AR mediated transcription at low androgen levels [15]. Activation of AR by phosphorylation can also act as a means of cross-talk with other signaling pathways, particularly in a low androgen environment relevant to CRPCa. For example, EGF signaling results in phosphorylation at S515 to promote growth in androgen-free conditions [23]. A recent report shows that AR S213 phosphorylation likely identifies cells with catalytically active PIM1 and is correlated with CRPCa [24]. In addition, phosphorylation of AR at Y267 by Ack1 is correlated with PCa radiation treatment resistance in CRPCa patients [25]. In contrast to most p-AR associated with poor prognosis, a recent study showed phosphorylation at S308 and S791 can predict enhanced survival in CRPCa [26]. It is of great interest to determine whether any of these phosphorylation sites for AR are directly causal of CRPCa development. With increased understanding of the mechanisms and function of AR phosphorylation, there is greater potential for development of therapeutic targets or prognostic markers for PCa.

There is still much left to be understood about the role of AR phosphorylation in PCa. For example, splicing variants of AR have been discovered that are constitutively active in the absence of androgens [27]. The impact of AR phosphorylation on the expression and function of these recently identified truncated [28] and membrane [29] variants of AR is not known. Targeting kinases which phosphorylate sites in the truncated variants may be an effective means of treatment under conditions where
AR phosphorylation in prostate cancer

androgen ablation therapy would have no effect.

AR expression and activity in cancer epithelial cells has been the primary focus of study in PCa research over the years. However, more recent studies implicated the increased importance of the stromal cells in regulating PCa growth. Multiple in vitro cell culture models are now available for the study of AR functions [30]. Conditioned media from stromal cells can lead to S81 phosphorylation of AR in PCa cells [31]. Additionally, AR signaling in the stromal cells is also important in the regulation of surrounding PCa epithelial cell proliferation. For example, stromal AR can inhibit growth of PCa cells in the presence of androgen in co-culture and co-xenograft studies [32]. Further, studies with P-S213 AR antibody showed increased detection of phosphorylation at S213 in epithelial cells but no expression in surrounding stromal cells in PCa [33]. There has been very limited research on the role of stromal AR in PCa, and particularly the phosphorylation status of stromal AR. Many potential therapies work very well in cell culture but fail in vivo and much of this could be due to activity in the stromal microenvironment. As continued studies show the importance of AR activity in PCa stromal cells, it will also be important to identify the role of phosphorylation in AR positive stromal cells on PCa progression. Increased understanding of the complex combination of phosphorylation signals in the AR in both cancer and cancer-associated stroma cells will undoubtedly lead to more successful treatments in PCa.

Of note, PCa has been described as a more aggressive cancer in African American (AA) compared to Caucasian (CA) patients [34-36]. Further, epithelial AR expression has been shown to be increased [37] and stromal AR decreased [38] more frequently in AA PCa in comparison to CA patients. It is of great interest to determine whether AA PCa possess changes in AR splice variants and if there are differences in phosphorylation status, both in the cancer epithelial and cancer associated stromal cells, that make these cancers more aggressive.

New research has shown unique roles of various kinases that regulate AR to ultimately modulate effects on cell growth and these kinases may be used as the primary targets for battling prostate cancer. As the roles of site-specific AR phosphorylation are elucidated, it is important to note that each site works in conjunction with others, as well as additional PTMs of AR. Continued research is necessary to evaluate the function of phosphorylation at each phospho-site but also learn how the various AR PTMs work together to modulate cell homeostasis in either genomic or non-genomic pathways. Identification of single p-AR modifications may not be predictive of cell behavior outside of the context of other PTMs of AR. Disparate activities at separate phospho-sites concurrently may explain some of the discrepancies found in the literature on p-AR functions. More detailed understanding of how the specific phosphorylation activities work together will ultimately lead to more effective combinatorial treatments.

Acknowledgements

This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (Biomedical Laboratory Research and Development). This study is funded by NIH (1U01CA149556-01), DOD PCRP (PC080010 and PC11624) and VA Merit (I1I01BX001505-01) grants to PL, NYU Molecular Oncology and Immunology Postdoctoral Training grant (T32 CA009161) to GD.

Address correspondence to: Dr. Peng Lee, Department of Pathology and Urology, New York Harbor Healthcare System, New York University School of Medicine, 423 E. 23rd street, Room 6139N, New York, NY 10010, USA. E-mail: peng.lee@nyumc.org

References


AR phosphorylation in prostate cancer


AR phosphorylation in prostate cancer


